Pyrotinib for first treatment of HER2-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have stage IIIB or IV non-small cell lung cancer (NSCLC).
- You have not had any prior “systemic” anti-cancer treatment for stage IIIB/IV NSCLC (no prior chemo/tablets/targeted cancer drugs).
- Your tumor (or blood) tests show a primary HER2 change: an insertion mutation, a point mutation, or HER2 amplification.
- Your scans show at least one measurable tumor spot, and you can expect to live at least 12 weeks.
- Your body is strong enough for treatment: good blood counts, liver and kidney test results, and heart function with left-ventricle pumping fraction (LVEF) 50% or higher.
- You can take pills and there are no recent trial-drug/major-surgery issues that would interfere with safety or timing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two targeted medicines for people with advanced non-small cell lung cancer that has a specific HER2 gene change and has progressed after standard treatment. The goal is to see if the combination can shrink tumors or slow cancer growth.
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
This study tests whether taking pyrotinib (a daily pill) with capecitabine (another pill) after breast cancer surgery can help prevent HER2-positive early-stage breast cancer from coming back. It is for women who have already had their cancer removed and meet certain risk criteria.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.